Renova Therapeutics
Carlsbad, US · 1 known investors
Renova Therapeutics develops investigational gene therapies intended as single-dose, long-lasting treatments for common chronic diseases, with an initial focus on congestive heart failure and type 2 diabetes. The company builds a platform of therapeutics and delivery systems based on proprietary insights into disease mechanisms.
Founders & leadership
KH
Kirk HammondDirector
SS
Shawn SwaneyExecutive Officer
RC
Roy CosanDirector
PL
Pierre LecocqDirector
VM
Vijay MahantDirector
MT
Michael TorresDirector
WD
William DavidsonDirector
MX
Morgan XuDirector
Investors · 1
Reported raises · per SEC filings
Form D private placements▶$166.5KraisedSep 2024 · 7 investors · BiotechnologyRule 506(b)
▶$166.5KraisedSep 2024 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Roy CosanDirector
- Pierre LecocqDirector
- Vijay MahantDirector
- Michael TorresDirector
- Kirk HammondDirector
- William DavidsonDirector
- Morgan XuDirector
- Shawn SwaneyExecutive Officer
- Offering amount
- $500K
- Amount sold
- $166.5K
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2022 | $1.6M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2019 | $241.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2016 | $1.6M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2014 | $240.8K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.